CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 20 enrolled / 20 target
Drug / intervention
Belantamab mafodotin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07150091
NCT07150091Phase 1ActiveUpdate Overdue (0.4/mo)Completion was 14mo ago
CompareCT.gov

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination

GlaxoSmithKline·interventional·Posted Sep 2, 2025·Updated Jun 16, 2026

In Brief

A Phase 1 clinical trial evaluating Belantamab mafodotin, Nirogacestat, and 2 other interventions for Multiple Myeloma. Active but no longer recruiting, targeting 20 participants across 12 sites in 8 countries.

Signals

Enrollment appears stalled

Detailed Summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, lenalidomide, and dexamethasone, and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesBrazil, Canada, France, Germany, Greece, Mexico, South Korea, United States
Collaborators--

Timeline

Phase 1Active
20232024202520262027
First PostedSep 2, 2025
Enrollment StartJul 19, 2022
Primary CompletionApr 17, 2025
Study CompletionMar 11, 2027
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10 months ago

Arms & Interventions

Belantamab mafodotin + Nirogacestat + Lenalidomide + Dexamethasoneexperimental

Drug: Belantamab mafodotinDrug: NirogacestatDrug: LenalidomideDrug: Dexamethasone

Interventions

Belantamab mafodotindrug

Belantamab mafodotin will be administered.

Nirogacestatdrug

Nirogacestat will be administered.

Lenalidomidedrug

Lenalidomide will be administered.

Dexamethasonedrug

Dexamethasone will be administered.